Assetmark Inc. lessened its holdings in shares of Humana Inc (NYSE:HUM) by 2.1% during the third quarter, according to the company in its most recent Form 13F filing with the SEC. The firm owned 36,922 shares of the insurance provider’s stock after selling 795 shares during the period. Assetmark Inc.’s holdings in Humana were worth $12,499,000 as of its most recent filing with the SEC.
Several other large investors have also modified their holdings of the company. Financial Gravity Wealth Inc. lifted its holdings in shares of Humana by 41.9% during the third quarter. Financial Gravity Wealth Inc. now owns 562 shares of the insurance provider’s stock worth $179,000 after purchasing an additional 166 shares during the period. Carillon Tower Advisers Inc. lifted its holdings in shares of Humana by 0.6% during the third quarter. Carillon Tower Advisers Inc. now owns 27,160 shares of the insurance provider’s stock worth $9,194,000 after purchasing an additional 168 shares during the period. San Francisco Sentry Investment Group CA lifted its holdings in shares of Humana by 46.9% during the third quarter. San Francisco Sentry Investment Group CA now owns 598 shares of the insurance provider’s stock worth $203,000 after purchasing an additional 191 shares during the period. Oppenheimer Asset Management Inc. lifted its holdings in shares of Humana by 1.7% during the second quarter. Oppenheimer Asset Management Inc. now owns 11,901 shares of the insurance provider’s stock worth $3,541,000 after purchasing an additional 197 shares during the period. Finally, CIBC World Markets Inc. lifted its holdings in shares of Humana by 0.7% during the third quarter. CIBC World Markets Inc. now owns 30,069 shares of the insurance provider’s stock worth $10,179,000 after purchasing an additional 198 shares during the period. Institutional investors own 92.90% of the company’s stock.
In other Humana news, insider Roy A. Beveridge sold 4,622 shares of Humana stock in a transaction on Thursday, November 8th. The shares were sold at an average price of $341.06, for a total value of $1,576,379.32. Following the completion of the sale, the insider now directly owns 10,621 shares of the company’s stock, valued at $3,622,398.26. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Bruce D. Broussard sold 18,000 shares of Humana stock in a transaction on Monday, September 10th. The shares were sold at an average price of $328.66, for a total transaction of $5,915,880.00. Following the completion of the sale, the chief executive officer now directly owns 71,085 shares of the company’s stock, valued at $23,362,796.10. The disclosure for this sale can be found here. Insiders own 0.60% of the company’s stock.
Shares of NYSE HUM opened at $306.00 on Friday. Humana Inc has a twelve month low of $242.00 and a twelve month high of $355.88. The firm has a market cap of $44.51 billion, a P/E ratio of 26.13, a PEG ratio of 1.54 and a beta of 0.99. The company has a quick ratio of 1.68, a current ratio of 1.68 and a debt-to-equity ratio of 0.45.
Humana (NYSE:HUM) last announced its earnings results on Wednesday, November 7th. The insurance provider reported $4.58 earnings per share for the quarter, topping analysts’ consensus estimates of $4.29 by $0.29. Humana had a net margin of 2.70% and a return on equity of 19.10%. The business had revenue of $14.21 billion during the quarter, compared to the consensus estimate of $13.97 billion. During the same quarter last year, the firm earned $3.39 earnings per share. On average, research analysts predict that Humana Inc will post 14.43 EPS for the current fiscal year.
The business also recently declared a quarterly dividend, which will be paid on Friday, January 25th. Shareholders of record on Monday, December 31st will be paid a $0.50 dividend. This represents a $2.00 annualized dividend and a yield of 0.65%. The ex-dividend date is Friday, December 28th. Humana’s dividend payout ratio (DPR) is currently 11.96%.
A number of equities analysts have recently commented on the stock. Zacks Investment Research upgraded shares of Humana from a “hold” rating to a “buy” rating and set a $373.00 price target on the stock in a report on Thursday. ValuEngine lowered shares of Humana from a “buy” rating to a “hold” rating in a report on Friday. Cowen assumed coverage on shares of Humana in a report on Monday, September 17th. They set a “market perform” rating and a $372.00 price target on the stock. Credit Suisse Group lifted their price target on shares of Humana from $370.00 to $390.00 and gave the stock an “outperform” rating in a report on Thursday, November 8th. Finally, MED lifted their target price on shares of Humana from $350.00 to $373.00 and gave the stock an “outperform” rating in a research note on Thursday, November 8th. Seven research analysts have rated the stock with a hold rating and fourteen have assigned a buy rating to the company. Humana currently has an average rating of “Buy” and a consensus price target of $352.10.
COPYRIGHT VIOLATION NOTICE: “Humana Inc (HUM) Shares Sold by Assetmark Inc.” was published by American Banking News and is the property of of American Banking News. If you are reading this story on another site, it was stolen and republished in violation of United States and international copyright and trademark legislation. The legal version of this story can be viewed at https://www.americanbankingnews.com/2018/12/08/humana-inc-hum-shares-sold-by-assetmark-inc.html.
Humana Inc, together with its subsidiaries, operates as a health and well-being company in the United States. The company operates through four segments: Retail; Group and Specialty; Healthcare Services; and Individual Commercial. The Retail segment offers Medicare and supplemental benefit plans to individuals or through group accounts.
Recommended Story: Cash Flow
Want to see what other hedge funds are holding HUM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Humana Inc (NYSE:HUM).
Receive News & Ratings for Humana Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Humana and related companies with MarketBeat.com's FREE daily email newsletter.